Inventiva S.A. (NASDAQ:IVA) Receives $17.00 Consensus PT from Analysts

Shares of Inventiva S.A. (NASDAQ:IVA) have received a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $17.00.

IVA has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Inventiva in a research note on Monday, April 1st. Canaccord Genuity Group lifted their price target on Inventiva from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, April 8th.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new stake in shares of Inventiva S.A. (NASDAQ:IVA) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

NASDAQ:IVA opened at $2.95 on Wednesday. The business has a 50 day moving average of $3.30 and a 200 day moving average of $3.65. Inventiva has a 1-year low of $2.52 and a 1-year high of $4.75.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.